Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PaTHway CHINA TRIAL: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial, With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With Hypoparathyroidism

NCT05387070 is registered in ClinicalTrials.gov with Visen Pharmaceuticals (Shanghai) Co., Ltd. as lead sponsor.

NCT NCT05387070
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05387070 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PaTHway CHINA TRIAL: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial, With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With Hypoparathyroidism
Lead sponsor
Visen Pharmaceuticals (Shanghai) Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
July 28, 2021
Completion date
January 8, 2026
Enrollment
81 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endocrine system diseases, hypoparathyroidism, parathyroid diseases, parathyroid hormone deficiency